NCT04525157Phase 2Completed

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

Study sponsor: Clinuvel Pharmaceuticals Limited

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2016-02-02Actual

Enrollment · participants21Actual

Source updated2023-09-22Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Vitiligo

Treatments or interventions studied

AfamelanotideDrug
PlaceboDrug

Primary outcomes · main study measures

measure: Change in Pigmentation (Total and Individual Body Parts) Using the Vitiligo Area Scoring Index (VASI); description: A decrease in VASI over time indicates a reduction of the body surface area affected by vitiligo and/ or a reduction in the body sites' degree of depigmentation (possible range 1-100); timeFrame: From Day 0 to Day 196

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history